 SUZHOU and SHANGHAI, China, April 23, 2021 GLOBE NEWSWIRE -- Gracell Biotechnologies Inc. NASDAQ: GRCL Gracell, a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the company has filed its annual report on Form 20-F for the full year ended December 31, 2020 with the U.S. Securities and Exchange Commission SEC on April 23, 2021. 